By Delilah Alvarado
Published May 14, 2026
In a significant boost for the next generation of immunotherapy, Cambridge-based biotechnology firm Create Medicines announced on Thursday that it has successfully closed a $122 million Series B financing round. The capital infusion is earmarked to accelerate the company’s ambitious pipeline of RNA-based, in vivo CAR-T cell therapies, which aim to treat a broad spectrum of oncological and autoimmune conditions.
The funding round was co-led by a consortium of heavyweight industry investors, including Arch Venture Partners, Newpath Partners, and Hatteras Venture Partners. Participation also extended to Alexandria Venture Investments and existing members of the company’s investor syndicate, signaling strong institutional confidence in Create’s proprietary platform.
The Technological Leap: From Ex Vivo to In Vivo
At the heart of Create Medicines’ value proposition is a departure from the traditional, laborious manufacturing processes associated with current CAR-T therapies. Standard CAR-T treatments—which have revolutionized blood cancer care—typically require the extraction of a patient’s T cells, genetic modification in a laboratory, and re-infusion. This "ex vivo" process is not only expensive and time-consuming but also creates logistical bottlenecks that limit patient access.
Create Medicines is pioneering an in vivo approach. By leveraging a specialized messenger RNA (mRNA) and lipid nanoparticle (LNP) delivery platform, the company can deliver genetic instructions directly into the patient’s body. Once administered, these nanoparticles home in on specific immune cells—T cells, NK cells, and myeloid cells—effectively turning the patient’s own body into a bioreactor.
This process offers what the company describes as a "one-day manufacturing" capability. By bypassing the need for complex, centralized cell-processing facilities, Create hopes to democratize access to these potent therapies, potentially reducing costs and patient wait times significantly.
A Chronology of Evolution: From Myeloid to Create
The journey to this $122 million milestone has been marked by strategic pivots and high-profile leadership. Founded in 2021 as Myeloid Therapeutics, the startup initially captured industry attention by focusing specifically on the myeloid cell lineage—a class of immune cells often overlooked by standard CAR-T therapies.
The company was built upon the vision of two heavyweights in their respective fields: Ronald Vale, an entrepreneur and co-founder of the biotechnology titan Cytokinetics, and Siddhartha Mukherjee, the renowned biologist and Pulitzer Prize-winning author. Their foundational research provided the scientific rigor necessary to translate complex cell biology into clinical applications.
By 2025, the company recognized that its platform’s potential extended far beyond myeloid-focused treatments. As it expanded its clinical scope to include experimental RNA-based, in vivo CAR-T therapeutics, the board initiated a comprehensive rebranding. In a move to better represent its diversified therapeutic focus, the company officially became Create Medicines. This transition was not merely cosmetic; it signaled a strategic shift toward becoming a broad-spectrum immune-programming powerhouse.
Supporting Data and Clinical Momentum
Unlike many early-stage biotech firms that rely heavily on preclinical models, Create Medicines has already established a robust clinical presence. To date, the company has dosed more than 50 patients across its various programs, a milestone that executives claim represents the largest clinical dataset in the in vivo CAR-T space.
The MT-304 Milestone
The company’s most recent clinical progress involves MT-304, a first-in-class, multi-immune, in vivo CAR therapy. Last month, Create dosed the first patient in a Phase 1/2 trial for MT-304, which is designed to target the HER2 protein.
HER2 is a protein often overexpressed in various cancers, including breast and gastric tumors. MT-304 is designed to trigger multiple arms of the immune system simultaneously, offering a more aggressive and coordinated response than traditional monotherapies. The trial is currently evaluating the safety and preliminary efficacy of this candidate in patients with HER2-positive solid tumors, a group that has historically been difficult to treat with first-generation CAR-T therapies.
Autoimmune Expansion
Beyond oncology, Create is actively testing its platform in the autoimmune space. By leveraging the same mRNA-LNP technology to target proteins like CD19 and BCMA—which are currently the industry standard targets for approved CAR-T blood cancer medicines—the company is exploring whether it can reprogram the immune system to stop attacking healthy tissue in autoimmune conditions. This "re-purposing" of established targets into new therapeutic contexts is a hallmark of the company’s lean, high-efficiency research model.
Leadership Changes and Governance
The influx of capital is accompanied by a significant strengthening of the company’s leadership team. Alongside the financing announcement, Create revealed that biotech veteran Ron Philip has been appointed as Executive Chairman.
Philip, whose career has spanned decades of drug development and commercial strategy, expressed high optimism regarding the firm’s trajectory. "I am excited to join Create at this pivotal moment in the company’s evolution," Philip stated. "Create has established meaningful in vivo clinical proof points and built a differentiated immune programming platform with the potential to redefine how engineered immune therapies are developed and delivered."
The board of directors has also seen strategic additions to bolster its oversight. Brian Cuneo, a senior partner at Arch Venture Partners, and Tom Thomas, a senior associate at Newpath Partners, have joined the board. Their presence ensures that the company remains aligned with the strategic goals of its primary financial backers as it prepares for the next phase of its clinical trials.
Strategic Implications for the Biotech Landscape
The success of Create Medicines’ Series B round carries broader implications for the immunotherapy sector.
1. The Death of Logistics Barriers
If in vivo therapies prove as safe and effective as their ex vivo counterparts, the entire manufacturing ecosystem for cell therapy will be upended. The capital-intensive nature of cleanroom facilities and viral vector production may be replaced by synthetic mRNA production, which is significantly more scalable and cost-effective.
2. Broadening the Patient Base
Traditional CAR-T therapies have been largely restricted to blood-borne cancers due to the difficulty of getting cells to migrate to solid tumors. By reprogramming cells directly within the tissue microenvironment, Create’s in vivo approach holds the potential to tackle "cold" solid tumors—a long-standing "holy grail" for the field of immuno-oncology.
3. The Rise of "Immune Programming"
The term "immune programming" is increasingly replacing "cell therapy" in industry lexicon. Create’s focus suggests a future where medicine acts as a software update for the human immune system. By using mRNA to provide instructions, the company is effectively treating the body as a programmable biological computer.
Looking Ahead: The Path to Commercialization
With $122 million in fresh capital, Create Medicines is well-positioned to navigate the "valley of death" that often claims biotech startups between Phase 1 and Phase 3 trials. The funding will likely support the scaling of its manufacturing capabilities, the expansion of its Phase 1/2 clinical trials for MT-304, and the acceleration of its preclinical autoimmune assets.
However, the path forward is not without challenges. The regulatory landscape for in vivo genetic medicine is still evolving. The FDA and international regulators will be watching closely to ensure that direct-to-body reprogramming remains safe, specifically regarding off-target effects and potential systemic toxicity.
As Create Medicines moves into this next phase, the industry will be watching to see if it can convert its early clinical success into a commercially viable, standardized therapy. If successful, the company may well have created the blueprint for the next decade of medical intervention, turning the most complex therapies into accessible, off-the-shelf solutions. For now, the combination of strong financial backing, a proven clinical record, and a seasoned leadership team positions Create as a leader in the race to define the future of medicine.
